Susan M. Clardy - Concepedia

Author

Susan M. Clardy

Mersana Therapeutics (United States)ORCID

Also Known As

Susan Clardy, Susan M Clardy, Susan M. Clardy

Publications

798

Citations

H-Index

Concepts

All Affiliations

Mersana Therapeutics (United States)Center for Systems Biology Massachusetts General Hospital Harvard University Brigham and Women's Hospital

About

Susan M. Clardy is an author at Mersana Therapeutics (United States) specializing in medicine, radiation oncology, and immunotherapy.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	5	6	136
2	Engineering	1	1	55
3	Health Sciences	1	1	55
4	Natural Sciences	1	1	42
5	Allergy	1	1	25

Susan M. Clardy

Publications

641

Citations

H-Index

Page 1

	Year	Citations
Multiparametric plasma EV profiling facilitates diagnosis of pancreatic malignancy Katherine S. Yang, Hyungsoon Im, Seonki Hong, Science Translational Medicine	2017	287
Epigenetic modulation of type-1 diabetes via a dual effect on pancreatic macrophages and β cells Wenxian Fu, Júlia Farache, Susan M. Clardy, eLife	2014	85
Dolaflexin: A Novel Antibody–Drug Conjugate Platform Featuring High Drug Loading and a Controlled Bystander Effect Aleksandr V. Yurkovetskiy, Natalya D. Bodyak, Mao Yin, Molecular Cancer Therapeutics	2021	70
In Vivo Imaging of GLP-1R with a Targeted Bimodal PET/Fluorescence Imaging Agent Christian Brand, Dalya Abdel-Atti, Yachao Zhang, Bioconjugate Chemistry Vivo ImagingEngineeringOncologic ImagingImaging AgentPeptide Science	2014	55
Fluorescent Exendin-4 Derivatives for Pancreatic β-Cell Analysis Susan M. Clardy, Edmund J. Keliher, James F. Mohan, Bioconjugate Chemistry Peptide SciencePancreas TransplantationGlp1r LigandInsulin SignalingPancreatic Cancer	2013	42
Abstract 6706: Systemic administration of STING agonist antibody-drug conjugates elicit potent anti-tumor immune responses with minimal induction of circulating cytokines Raghida A. Bukhalid, Jeremy R. Duvall, Naniye Mallı Cetinbas, Cancer Research Minimal InductionImmunologyImmunologic MechanismBiological TherapyInnate Immunity	2020	25
Abstract 3503: XMT-2056, a HER2-targeted Immunosynthen STING-agonist antibody-drug conjugate, binds a novel epitope of HER2 and shows increased anti-tumor activity in combination with trastuzumab and pertuzumab Jeremy R. Duvall, Raghida A. Bukhalid, Naniye Mallı Cetinbas, Cancer Research ImmunologyImmunoeditingNovel EpitopeImmunotherapeuticsSting Agonist	2022	24
Abstract 1738: XMT-2056, a well-tolerated, Immunosynthen-based STING-agonist antibody-drug conjugate which induces anti-tumor immune activity Jeremy R. Duvall, Raghida A. Bukhalid, Naniye Mallı Cetinbas, Cancer Research NanotherapeuticsAbstract 1738ImmunologyImmunoeditingSting Pathway	2021	23
Rapid, high efficiency isolation of pancreatic ß-cells Susan M. Clardy, James F. Mohan, Claudio Vinegoni, Scientific Reports	2015	19
Abstract 2894: XMT-1592, a site-specific Dolasynthen-based NaPi2b-targeted antibody-drug conjugate for the treatment of ovarian cancer and lung adenocarcinoma Shawn P. Fessler, Anouk Dirksen, Scott D. Collins, Cancer Research Lung AdenocarcinomaImmunotherapeuticsDolasynthen PlatformCancer BiologyTumor Biology	2020	11

Page 1